Methotrexate is currently the most commonly prescribed basic drug for rheumatoid arthritis worldwide. Sixty to eighty per cent of patients receive this drug. However, the problem is that methotrexate is driven out of cells and tissues too quickly to be optimally effective. With its NovoBioMed technology, Amplio Pharma aims to increase the effectiveness of methotrexate. It does this by adding novobiocin, which acts as a kind of lock-keeper, temporarily inhibiting the outflow pump in the cell (the \u2018doors\u2019 through which methotrexate is normally pumped out again), so that methotrexate stays longer in the inflammatory cells and can do its work there more powerfully. Amplio Pharma works with already known substances, therefore much is already known about the safety of these substances and this accelerates the clinical development of the drug. Amplio Pharma is supported in the development of NovoBioJect by an international team of industry veterans and by collaborations with academic centres such as the LUMC and the Amsterdam UMC.<\/p>","protected":false},"author":12,"featured_media":9802,"template":"","tags":[47,95,134,135,90,83],"gc-fonds":[52],"class_list":["post-9809","gamechangers","type-gamechangers","status-publish","has-post-thumbnail","hentry","tag-investeren","tag-lsh","tag-mkb-fonds-2","tag-visie-mkb-fonds","tag-voor-vrouwen","tag-zorgtransitie","gc-fonds-mkb-fonds"],"yoast_head":"\n